Efficacy,Safety And Economic Evaluation Of Xiaoruzeng Capsule In The Treatment Of Breast Hyperplasia

Objective : Taking pharmaceutical specifications,expert consensus,and clinical experience as the principle of medication and combining current medical environment to evaluate the advantages of using commercially available medicines and hospital preparations,in other words,to evaluate the clinical efficacy and safety of Xiaoruzeng capsule and Pingxiao capsule,and to investigate the economy;to evaluation the clinical efficacy and economic effect of five sets of drug regimens to breast hyperplasia in our hospital,achieving the goal of optimizing drugs,and assisting medical insurance control costs.Method:1.Totally,445 of cases,diagnosed breast hyperplasia in this hospital from Dec.2015 ~ Dec.2017,were divided into three groups according to their medications,? : Guizhifuling pill;?: Guizhifuling pill & Pingxiao capsule;?: Guizhifuling pill & Xiaoruzeng capsule.The data of cost and output indicators for cost-effectiveness and cost-utility were analyzed by comparing their grading-score and total effective rate according to the changes of five indexes on breast pain,tenderness,magnitude,distribution and texture of the mass.2.Added up to 374 of patients with breast hyperplasia were chosen,and settled in single-drug groups or combined-drug groups,and finally five groups were involved in,?: Xiaoruzeng capsule;?: Pingxiao capsule;?: Xiaoruzeng capsule & Pingxiao capsule;? : Xiaoruzeng capsule & Dahuangzhechong tablet;? : Pingxiao capsule & Dahuangzhechong tablet.A retrospective analysis was used to evaluate their grading-score,efficacy-side effect and cost-effect,according to the changes of five indexes on breast pain,tenderness,magnitude,distribution and texture of the mass.Result:1.The total effective rates of the three treatment regimens were 53.48%,75.74% and 89.71%;the total adverse reactions were 4.65%,16.18% and 6.70%;the cost-effectiveness ratios were 20.28,19.76,and 14.40,respectively.On the basis of the program,the additional costs for each 1% increase in efficiencies in groups II and III were 18.50 and 5.71,respectively;and the sensitivity analysis was consistent with the cost-benefit analysis.After 2 cycles of treatment,patients in group II were gotten 0.54 of QALY and 0.61 of QALY for group III.2.The effective rates of five groups were 78%,69%,94%,89% and 87%;cost-effective ratio were 6.19,9.97,9.52,9.36 and 11.94,respectively.Based on the lowest cost calculation,the single-drug group was based on the group I regimen.?C/?E of group II was-22.77.In the combination group,on the basis of group IV,the supplemental cost to each unit are 12.81 in ? and-107.58 in ?,respectively.The results of sensitivity analysis were consistent with the results of cost-effect analysis.Conclusion: Xiaoruzeng capsule have desirable clinical efficacy,safety,and economic advantages in the treatment of breast hyperplasia;According to the five medicate treatments in our hospital,although,the single use of Xiaoruzeng capsuleis cheaper,but the effective rate is relatively lower,too;thus the drug combination should be considered.while,the set of Xiaoruzeng capsule & Pingxiao capsule has desirable clinical efficacy and economic advantages.The study provides a scientific basis for clinical safe,effective,rational and economical drug use.